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Introduction 63
Recent work characterising the hepatic proteome has identified 168 proteins which can be 64 secreted and potentially exert endocrine-like effects in distal sites (Meex et al. 2015) . A 65 number of these 'hepatokines' are associated with measures of adiposity (Chen et prompted suggestions that hepatokines represent a potential mechanism linking adiposity and 70 metabolic health and may be novel therapeutic targets to combat obesity-related insulin 71 resistance and associated metabolic disease. 72
73
To date, much of the research concerning hepatokine function and metabolism has focused on 74 their direct influence on tissue-specific insulin sensitivity and systemic glucose metabolism. 75
The most frequently studied, fibroblast growth factor-21 (FGF21), has been shown to 76 improve glucose metabolism in the liver, skeletal muscle and adipose tissue (Camporez et al. required to scrutinise the pathophysiological relevance of these novel proteins in vivo. 87 5 Current evidence demonstrates that exercise training reduces circulating levels of fetuin-A 88 and FGF21, and responses correlate with improvements in insulin sensitivity and intrahepatic 89 fat (Malin et al. 2013 , Taniguchi et al. 2016 . Given that single bouts of exercise 90 transiently enhance insulin sensitivity (Sylow et al. 2017 ), a handful of studies have also 91 investigated the acute influence of exercise on circulating hepatokines, speculating that 92 modulation of the hepatokine profile may be implicated in the benefits induced. This 93 hypothesis is strengthened by the knowledge that exercise acutely increases circulating non- The purpose of this study was two-fold. Firstly, we sought to investigate differences in 108 adiposity status on FGF21, follistatin, LECT2, SeP and fetuin-A in normal weight and 109 overweight/obese men. Secondly, we characterised the effect of an acute bout of moderate-110 intensity exercise on circulating concentrations of these hepatokines in order to explore their 111 potential role as mediators of exercise-induced improvements in glycaemic control and other 112 6 metabolic parameters. We hypothesised that overweight/obese individuals would have 113 elevated circulating concentrations of hepatokines at rest and that an acute bout of moderate-114 intensity exercise would beneficially alter circulating hepatokine profiles; by reducing 115 LECT2, SeP, and fetuin A, whilst increasing FGF21 and follistatin. 116
Materials and methods 117

Ethical approval and participant recruitment 118
After receiving approval from the East Midlands NHS Research Ethics committee 119 (13/EM/0290), 22 non-smoking men were recruited equally into normal weight and 120 overweight/obese groups (BMI: 18.5 to 24.9 and 25.0 to 34.9 kg•m -2 , respectively); providing 121 written, informed consent to participate. This sample size was chosen based on previous 122 studies that documented significant changes in hepatokines (FGF21 and follistatin) in 123 response to acute exercise; as well as differences between participant groups (normal weight 124 vs. obese and normal vs. impaired glucose regulation) (Slusher et al. 2015 , Hansen et al. 125 2016a , 2016b . Participants in the current study were free of diagnosed chronic disease and 126
were not taking medications known to affect glucose or lipid metabolism, or blood pressure. test on a motorised treadmill (Excite Med, Technogym, Italy), which was subsequently 144 followed by a ramped peak oxygen uptake test. Expired air was collected continuously 145 throughout both tests for quantification of oxygen consumption (V̇O 2 ) and carbon dioxide 146 production (V̇CO 2 ) using breath-by-breath indirect calorimetry (Metalyser 3B, Cortex, 147
Germany). Peak oxygen uptake (V̇O 2 peak) was calculated and bivariate linear regression was 148 used to estimate the treadmill speed necessary to elicit 60% of V̇O 2 peak during exercise trials. 149
150
In the 48 h before main trials, participants refrained from strenuous physical activity, alcohol 151 and caffeine, and standardised their dietary intake using weighed records. On the evening 152 before main trials, participants were provided with a standardised meal (3138 kJ; 71% 153 carbohydrate, 18% fat, 11% protein) to consume before 21:00 after which only water was 154 permitted until the start of the trials. 155 156
Experimental trials 157
Participants completed two experimental trials, control and exercise, in a counterbalanced 158 order and separated by approximately one week. On the morning of each trial, participants 159 arrived at the laboratory at 08:30, at which point an intravenous cannula (21 G; Venflon, 160
Becton Dickinson, Sweden) was inserted into an antecubital vein. Trials were then initiated 161 with a venous blood sample taken at ~09:00 (0 h) and additional samples were collected at 1, 162 1.5, 2.75, 4 and 7 h. During exercise trials, participants completed a 60-min bout of 163 moderate-intensity treadmill exercise (60% of V̇O 2 peak) between 0 and 1 h, and then rested 164 in the laboratory for the remainder of the trial (1-7 h). Heart rate (RS100, Polar, United 165 Kingdom) and rate of perceived exertion (RPE) (Borg 1970) were recorded every 15 min 9 during exercise, and expired air was collected throughout for ongoing measurement of V̇O 2 167 and V̇CO 2 . If necessary, treadmill speed was adjusted to maintain the desired exercise 168 intensity. Participants rested for the entirety of control trials and samples of expired air were 169 collected between 0 and 1 h to quantify resting energy expenditure; allowing the calculation 170 of net energy expenditure elicited by exercise. Participants were provided with a standardised 171 breakfast (2690 kJ; 72% carbohydrate, 18% fat, 10% protein) and lunch (3138 kJ; 43% 172 carbohydrate, 25% fat, 32% protein) at 1.5 and 4 h, respectively. Plasma volume was calculated in each whole blood sample using established equations (Dill 193 and Costill 1974). Circulating protein concentrations were corrected, as previously described 194 (Sherk et al. 2013 ), when plasma volume deviated significantly from baseline. 195
Statistical analyses 196
Unless otherwise stated, data are presented as mean ± SD or SEM for participant 197 characteristics and outcome variables, respectively. Statistical analyses were performed using 198 commercially available software (SPSS version 23.0, SPSS Inc., United States). Where 199 appropriate, data were log transformed to meet assumptions for parametric statistical testing. After inspection of main effects, the three-way interaction between trial, time and group was 210 used to assess whether hepatokine responses during and after exercise, when compared to the 211 control trial, differed between normal weight and overweight/obese groups. When this was 212 not significant, the two-way interaction between trial and time was used to investigate the 213 hepatokine response to exercise in the two groups combined. Statistically significant two-way 214 interactions were investigated further with two-tailed paired samples t-tests to identify the 215 the sample size in this study, no correction for multiple comparisons was applied. To help 217 clarity in graphical presentation, total area under the concentration-time curve (AUC) was 218 also calculated for each experimental trial and these data were analysed statistically using 219 two-way mixed design ANOVA. Probability (P-) values ≤ 0.05 were considered statistically 220 significant. 221
Results 222
Participant characteristics 223
Descriptive characteristics of the normal weight and overweight/obese groups can be found in 224 Table 1 . By design, the overweight/obese group had higher BMI, body mass, body fat 225 percentage and waist circumference, but age was similar between groups. There was no 226 difference in absolute cardiorespiratory fitness between groups but relative fitness was 227 greater in the normal weight individuals due to their lower body mass. Fasted plasma glucose, 228
insulin and HOMA-IR were similar between groups, but fasted plasma lipids were greater in 229 the overweight/obese individuals, whilst Adipo-IR tended to be higher. There were no 230 significant differences in AST, ALT or GGT between groups (data not shown). 
Fasted plasma hepatokine concentrations and associations with metabolic variables 235
The overweight/obese individuals had greater fasted plasma concentrations of LECT2 and 236 FGF21, but fasted concentrations of follistatin, fetuin-A and SeP were similar between 237 groups (Table 1) . Fasted circulating LECT2 and FGF21 were positively correlated with each 238 other (rho 2 = 36.9%, P = 0.03), body mass, BMI, WC, body fat, NEFA, TAG, Adipo-IR and 239 glucagon (r 2 ≥ 19.4%, P ≤ 0.02 or rho 2 ≥ 17.6%, P ≤ 0.05), and negatively with relative V̇O 2 240 peak (r 2 ≥ 27.0%, P ≤ 0.01). FGF21 was also marginally positively correlated with fasted 241 plasma glucose (r 2 = 18.1%, P = 0.048), whilst LECT2 was strongly positively correlated 242 with HOMA-IR (rho 2 = 43.2%, P = 0.001). Significant negative correlations were found 243 between fasted concentrations of follistatin and the AST:ALT ratio (r 2 = 18.5%, P = 0.05), 244
fetuin-A and age (rho 2 = 25%, P = 0.02), and between fasted concentrations of SeP and ALT 245 13 (r 2 = 19.4%, P = 0.04). Further details of all significant correlations can be found in 246 supplementary material. 247 248
Exercise characteristics 249
Participants in the normal weight group exercised at a greater treadmill speed due to their 250 higher relative cardiorespiratory fitness. However, the relative intensity of the exercise 251 performed was similar between groups (Table 2) 
Circulating hepatokine responses to exercise 261
Plasma FGF21 concentrations were higher in the overweight/obese group, irrespective of trial 262 or time (Figure 1a ; P = 0.003), but there was no interaction between trial, time and group (P 263 = 0.19). With groups combined, there was a significant two-way interaction between trial and 264 time for circulating FGF21 (Figure 2a ; P < 0.001), and post-hoc analyses revealed that 265 circulating concentrations were significantly higher at 1, 1.5 and 4 h in the exercise trial, 266 compared with control (all P ≤ 0.005). Accordingly, the total AUC for FGF21 was 267 significantly greater in the overweight/obese compared with the normal weight individuals 268 (Figure 1b ; P = 0.003), and in the exercise versus the control trials ( Figure 2b ; P = 0.003). 269
However, there was no interaction between group and trial (P = 0.65). 270
271
Circulating follistatin was lower in the overweight/obese versus the normal weight group 272 ( Figure 1c ; P = 0.05), but the interaction between trial, time and group was not significant (P 273 = 0.94). In the whole study population, there was a significant two-way interaction between 274 trial and time for plasma follistatin (Figure 2c ; P = 0.001). Post-hoc analyses identified 275 significantly higher concentrations at 2.75, 4 and 7 h in the exercise trial (P ≤ 0.02). Similarly, 276 the total AUC for follistatin was significantly lower in the overweight/obese group (Figure 1d ; 277 P = 0.05) and greater in the exercise trials (Figure 2d ; P < 0.01), but there was no interaction 278 between group and trial (P = 0.41). 279
280
Circulating LECT2 was higher in the overweight/obese group versus the normal weight 281 group, (Figure 1e ; P = 0.009), but there was no interaction between trial, time and group (P = 282 0.38). For plasma concentrations of LECT2, the two-way interaction between trial and time 283
in the whole study population was also not significant (Figure 2e ; P = 0.06). The total AUC 284 analyses for LECT2 mirrored these results with a significantly greater AUC in the 285 overweight/obese group (Figure 1f ; P < 0.01), but no significant difference between the 286 control and exercise trials (Figure 2f ; P = 0.07) and no interaction between group and trial (P 287 = 0.45). and SeP (Figures 1j and 2j) were similar between groups and between trials, and there were 294 no significant interactions (all P ≥ 0.17). 
Circulating responses of NEFA, glucagon and insulin to exercise 301
Despite differences in the fasted state, circulating concentrations of NEFA were similar 302 between groups throughout experimental trials (P = 0.09), and there was no significant 303 interaction between trial, time and group (P = 0.13). However, with groups combined there 304 was a significant two-way interaction between trial and time (Figure 3a ; P < 0.001) and post-305 hoc analyses revealed significantly higher concentrations of NEFA in the exercise trial at 1, 306 1.5, 2.75 and 7 h (P ≤ 0.04). 307 308 Circulating concentrations of glucagon, insulin and glucagon to insulin ratio were also similar 309 between groups (P ≥ 0.27), and the three-way interactions between trial, time and group were 310 not significant for any of these outcomes (P ≥ 0.16). However, in the whole study population, 311 there were significant two-way interactions between trial and time for all of glucagon, insulin 312 and the glucagon to insulin ratio (Figure 3b-d ; P ≤ 0.03). Post-hoc tests revealed the glucagon 313 to insulin ratio was significantly greater at 1 and 1.5 h in the exercise trial when compared to 314 the control trial (P ≤ 0.02). This was primarily driven by significantly higher concentrations 315 of glucagon (P ≤ 0.01) and occurred despite significantly higher concentrations of insulin at 316 1.5 h in the exercise trial (P = 0.02). Glucagon remained elevated in the exercise trial at 2.75 317 h (P = 0.03) but the consequential increase in the glucagon to insulin ratio was not 318 statistically significant (P = 0.08). In the current study the responses of circulating FGF21 and follistatin to exercise were 396 similar in both normal weight and overweight/obese participants. It has been previously 397
shown that the FGF21 and follistatin responses to acute exercise are blunted in individuals 398 with T2DM, and this may be the result of differences in the exercise-induced changes in 399 circulating NEFA and the glucagon to insulin ratio (Hansen et al. 2016a ). Furthermore, the 400 response of FGF21 to 30 min of exercise at 75% V̇O 2 peak has been shown to be reduced in 401 obese individuals compared with healthy, normal weight controls (Slusher et al. 2015) . 402
Notably, although the participants in the study by Slusher and colleagues (Slusher et al. 2015 ) 403
were reportedly healthy, the obese group had a mean HOMA-IR of 4.36, which approaches 404 the 5.13 threshold previously used to distinguish insulin resistant individuals (Wildman et al. 405 2008) . The participants in the current study were free from chronic disease and fasted plasma 406 glucose, insulin and HOMA-IR suggested they were not insulin resistant. It could, therefore, 407 be speculated that exercise-induced increases in circulating FGF21 and follistatin are 408 maintained in overweight/obese individuals with preserved glycaemic control but not once a 409 degree of insulin resistance has developed. Notably, the exercise-induced changes in NEFA 410 and the glucagon to insulin ratio were no different between groups in the current study. This 411 speculative hypothesis, however, should be tested further. 412
413
The current study is the first to investigate the acute effects of aerobic exercise on fetuin-A, 414 This study is not without limitation. Most prominently, this trial was conducted using a 422 relatively small sample of normal weight and overweight/obese men. Given the lack of prior 423 evidence we were unable to determine a priori whether our sample size was sufficient for all 424 of our outcomes. The novel data presented in this manuscript may, however, be utilised to 425 inform power calculations for future studies, particularly those investigating the effects of 426 acute exercise on LECT2, SeP and fetuin-A. Our results also cannot be generalised to 427 individuals with chronic metabolic disease or women. Notably, we did not directly measure 428 intrahepatic fat or insulin sensitivity in the current study. These are important considerations 429 because the development of metabolic disease may influence hepatokine metabolism. 430 Furthermore, the heightened propensity for fatty liver development in men, and the potential 431 metabolic influence of sex hormones, underscores the necessity for additional research to be 432 undertaken in women. 433
434
In conclusion, this study has identified higher circulating concentrations of FGF21 and 435 LECT2, and lower follistatin, in overweight/obese men when compared to normal weight 436 individuals. Moreover, circulating FGF21 and follistatin are acutely increased after moderate-437 intensity aerobic exercise, and this beneficial shift in hepatokine profile is similar in both 438 groups. These data provide new information regarding the effect of adiposity on the 439 metabolism of several novel hepatokines and supports evidence for a potential role of FGF21 440 and follistatin in the metabolic response to exercise. Additional work is needed to better 441 understand the interaction between these novel proteins, obesity and chronic disease; as well 442 as to better define their interaction with exercise and other metabolic perturbations. 443
Tables 573 Table 1 V̇O 2 : oxygen uptake; V̇O 2 peak: peak oxygen uptake. Data presented as mean ± SD. * indicates 584 a statistically significant difference between groups (P < 0.05). 585 
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